CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Sorafenib is the first-line treatment for advanced HCC, but the anti-cancer effects remain to be improved as indicated by its low response rates and failure to prolong the progression-free sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zibo, Yuan, Tao, Yan, Fangjie, Ye, Song, Xie, Qin, Zhang, Bo, Lin, Nengmin, He, Qiaojun, Yang, Bo, Zhu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020089/
https://www.ncbi.nlm.nih.gov/pubmed/35440025
http://dx.doi.org/10.1186/s12885-022-09520-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020089/
https://www.ncbi.nlm.nih.gov/pubmed/35440025
http://dx.doi.org/10.1186/s12885-022-09520-5

Ejemplares similares